1,4-Bis[4-[(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl]phenoxy]-2-butene | 163300-62-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1,4-Bis[4-[(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl]phenoxy]-2-butene
• 英文别名: 2,2'-(((But-2-ene-1,4-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(1,2,4-oxadiazolidine-3,5-dione)；2-[[4-[(E)-4-[4-[(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl]phenoxy]but-2-enoxy]phenyl]methyl]-1,2,4-oxadiazolidine-3,5-dione
• CAS: 163300-62-7
• 化学式: C₂₂H₂₀N₄O₈
• 分子量: 468.423
• InChiKey: LUACLLSCZRRTIH-OWOJBTEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  136
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Drug comprising combination
  申请人：——

  公开号：US20030060488A1

  公开（公告）日：2003-03-27

  A TNF-&agr; inhibitor comprising an insulin sensitizer in combination with an HMG-CoA reductase inhibitor is useful as an agent for the prophylaxis or treatment of an inflammatory disease and the like.

  一种包含胰岛素增敏剂和HMG-CoA还原酶抑制剂的TNF-α抑制剂，可用作预防或治疗炎症性疾病等的药剂。
• Neovascularization inhibitors
  申请人：——

  公开号：US20030134884A1

  公开（公告）日：2003-07-17

  An angiogenesis inhibitor containing a compound represented by the formula 1 wherein R 4 is an optionally substituted hydrocarbon group and the like; Xa is a bond and the like; k is an integer of 1 to 3; Ya is an oxygen atom and the like; ring Ea is a benzene ring optionally having additional substituent(s); p is an integer of 1 to 8; R 5 is a hydrogen atom and the like; q is an integer of 0 to 6; r is 0 or 1; R 8 is a hydroxy group and the like; and R 6 and R 7 are hydrogen atoms and the like, or a salt thereof is useful as an agent for the prophylaxis or treatment of tumor and the like.

  一种含有由下式表示的化合物的血管生成抑制剂 其中R4是可选择地取代的碳氢基团等；Xa是键等；k是1到3的整数；Ya是氧原子等；环Ea是苯环，可选择地具有额外的取代基；p是1到8的整数；R5是氢原子等；q是0到6的整数；r为0或1；R8是羟基等；R6和R7是氢原子等，或其盐，可用作预防或治疗肿瘤等的药剂。
• Abc expression promoters
  申请人：——

  公开号：US20040077689A1

  公开（公告）日：2004-04-22

  The ABCA1 mRNA expression-promoting agent, LXR&agr; mRNA expression-promoting agent, ABCG1 mRNA expression-promoting agent, cholesterol efflux-promoting agent, cholesteryl ester accumulation-inhibiting agent, ACAT-1 mRNA expression-inhibiting agent and CEH mRNA expression-promoting agent of the present invention are excellent in the ability to control cholesterol distribution in the body and have low toxicity.

  本发明的ABCA1 mRNA表达促进剂、LXRα mRNA表达促进剂、ABCG1 mRNA表达促进剂、胆固醇外流促进剂、胆固醇酯积聚抑制剂、ACAT-1 mRNA表达抑制剂和CEH mRNA表达促进剂在控制体内胆固醇分布方面具有出色的能力和低毒性。
• NOVEL BISOXADIAZOLIDINE DERIVATIVE
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0696585A1

  公开（公告）日：1996-02-14

  A bisoxadiazolidinedione derivative of general formula (I) useful as an insulin-sensitivity improver, a pharmaceutically acceptable salt thereof, and a medicinal composition thereof, wherein (a) and (b) may be the same or different from each other and each represent an optionally substituted phenylene group, and L represents: (1) an oxygen atom, (2) a group of formula (II) (R¹ being a hydrogen atom or a lower alkyl group), (3) a group of the formula: -S(O)n- (n being 0, 1 or 2), (4) a group of the formula: -CO-, (5) a group of formula (III) or (IV) (R² being a hydrogen atom or a lower alkyl group), or (6) an alkylene or alkenylene group which may be substituted and interrupted by an oxygen atom and/or a sulfur atom, and the like.

  一种用作胰岛素敏感性改善剂的通式(I)的双噁二唑烷二酮衍生物、其药学上可接受的盐及其药物组合物，其中(a)和(b)可以相同或互不相同，且各自代表任选取代的亚苯基，L代表：(1) 氧原子，(2) 式 (II) 的基团（R¹ 为氢原子或低级烷基），(3) 式中的基团：-S(O)n-（n 为 0、1 或 2），(4) 式中的一个基团：-CO-，(5)式(III)或(IV)的基团（R²为氢原子或低级烷基），或(6)可被氧原子和/或硫原子取代和间断的亚烷基或烯基等。
• DRUG COMPRISING COMBINATION
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1254667A1

  公开（公告）日：2002-11-06

  A TNF-α inhibitor comprising an insulin sensitizer in combination with an HMG-CoA reductase inhibitor is useful as an agent for the prophylaxis or treatment of an inflammatory disease and the like.

  由胰岛素增敏剂与 HMG-CoA 还原酶抑制剂组合而成的 TNF-α 抑制剂可用作预防或治疗炎症等疾病的药物。